Implant maintenanceProject ID: 672075
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Novel dental implant maintenance instrument; Production scaling up and European market expansion
Całkowity koszt:EUR 71 429
Wkład UE:EUR 50 000
Topic(s):NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs
Zaproszenie do składania wniosków:H2020-SMEINST-1-2014See other projects for this call
System finansowania:SME-1 - SME instrument phase 1
Peri-implant disease (Mucositis and peri-implantitis) is a major and growing clinical problem in odontology, affecting 20-40 mill. patients in Europe, and the double worldwide. Labrida has developed, clinically documented and CE marked a novel, patented (pending) maintenance device for non-surgical management of peri-implant disease. It is a revision brush (“BioClean”), with bioresorbable bristles made of mono-filament chitosan fibres (Patented by Medovent, DE). It offers safer, more effective, less painful and faster treatment of peri-implant disease, where currently the clinical community is in search for adequate solutions. The instrument addresses a market in the range of Euro 1-2 billion annual turnover.
The device is in small scale production and sold commercially in Scandinavia (TRL 7), with most promising market response.
To meet the market opportunity, we will develop up-scaled production processes of advanced chitosan fibres, which is critical to increase overall production requirements. In addition, we have started development with clinical pilot testing of the next generation product, comprising chitosan bristles combined with antibiotics, with interesting clinical results. This may open a broader application field for deployment of these combinations of materials technologies, both within odontology and wider in medicine.
The overall planned project (Phase 2) comprises both industrial development of scaled up production technologies for the chitosan fibres of the currently marketed product , as well as development of the next generation product, combining advanced chitosan technologies with bioactive material, e.g. in nanospheres. In phase 1, we intend to refine the development plan of these product(s) for phase 2, including assessing more in detail the business case, and additional application areas, of the 2nd generation product.
Wkład UE: EUR 50 000
THEODOR LOVSTADS VEI 32